Nextcure to present at the h.c. wainwright 23rd annual global investment conference

Beltsville, md., sept. 07, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the h.c. wainwright 23rd annual global investment conference on september 13th.

NXTC Ratings Summary

NXTC Quant Ranking